Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
|Articles|November 14, 2008
Sartorius Stedim Biotech Acquires Wave Biotech
Author(s)BioPharm International Editors
Sartorius Stedim Biotech GmbH (SSB, Goettingen, Germany) has acquired the Swiss-based company, Wave Biotech AG (Tagelswangen, Switzerland).
Advertisement
Sartorius Stedim Biotech GmbH (SSB, Goettingen, Germany) has acquired the Swiss-based company, Wave Biotech AG (Tagelswangen, Switzerland). The two companies have already been closely working together since 2006; in addition to joint research projects, Sartorius Stedim Biotech has been exclusively marketing Wave’s entire product range that covers various types of single-use bioreactors and further equipment for biopharmaceutical research and manufacture. During the current financial year, SSB’s sales revenue with Wave products is expected to amount to approximately $12.7 million. The acquisition, which is subject to clearance by the antitrust authorities, is expected to be completed in December 2008. Financial terms were not disclosed.
Wave Biotech began as one company, and then split into two, Wave Biotech AG and Wave Biotech LLC. In 2007, GE Healthcare bought the US-based Wave Biotech LLC.
Advertisement
Related to this article
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
The half-life-extended antibody failed its primary endpoints in two Phase 2 SKYWAY sub-studies, so Spyre is dropping it in rheumatic diseases and moving it into a combination trial in hidradenitis suppurativa.
Biora will test oral adalimumab via its BioJet capsule vs injection in healthy volunteers, with dosing from December 2026 and data in early 2027.
Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
3
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
4
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
5